Power Law company profile

Hyperion Therapeutics

Biotech & Life Sciences · Dublin, Ireland · Founded 2006 · IPO 2012 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Investors

5 investors on Hyperion Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

NEA

Sofinnova Investments

Highland Capital Partners

Series B+ 2 investors entered at this stage

Panorama Capital

Bay City Capital

Patent intelligence

$20M patent portfolio · 3 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$20M

26.5× smaller than top peer ChemoCentryx ($524M)

3 active patent families

Where Hyperion Therapeutics innovates Hepatic encephalopathyEncephalopathyProdrugDosing regimenNitrogen

Above peer median on Market

Quality vs same-sector peers

Hyperion Therapeutics on the five Patsnap quality dimensions

Hyperion Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Hyperion Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Hyperion Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Hyperion Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo